|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9034300||GISKIT||Composition and method for medical imaging of body cavities|| |
(7 years from now)
|US9259494||GISKIT||Composition and method for medical imaging of body cavities|| |
(11 years from now)
|US9849199||GISKIT||Composition and method for medical imaging of body cavities|| |
(12 years from now)
Exem Foam Kit is owned by Giskit.
Exem Foam Kit contains Air Polymer-Type A.
Exem Foam Kit has a total of 3 drug patents out of which 0 drug patents have expired.
Exem Foam Kit was authorised for market use on 07 November, 2019.
Exem Foam Kit is available in foam;intrauterine dosage forms.
Exem Foam Kit can be used as use in sonohysterosalpinography to assess fallopian tube patency.
Drug patent challenges can be filed against Exem Foam Kit from 2023-11-08.
The generics of Exem Foam Kit are possible to be released after 11 February, 2036.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Nov 7, 2024|
NCE-1 date: 2023-11-08
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic